HLS Therapeutics Inc. (TSX:HLS)
Canada · Delayed Price · Currency is CAD | Market Cap | 137.92M -10.8% |
| Revenue (ttm) | 77.81M -1.8% |
| Net Income | -14.36M |
| EPS | -0.46 |
| Shares Out | 31.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 323,319 |
| Open | 4.210 |
| Previous Close | 4.260 |
| Day's Range | 4.000 - 4.410 |
| 52-Week Range | 4.000 - 5.765 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 7.35 (+66.67%) |
| Earnings Date | Aug 13, 2026 |
About HLS Therapeutics
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovas... [Read more]
Financial Performance
In 2025, HLS Therapeutics's revenue was $55.50 million, a decrease of -1.98% compared to the previous year's $56.62 million. Losses were -$12.43 million, -36.76% less than in 2024.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for HLS stock is "Buy." The 12-month stock price target is $7.35, which is an increase of 66.67% from the latest price.
News
HLS Therapeutics Inc Annual Shareholders Meeting Transcript
HLS Therapeutics Inc Annual Shareholders Meeting Transcript
HLS Therapeutics Transcript: AGM 2026
The meeting addressed financial statements, elected Directors, reappointed the Auditor, and approved the Long-Term Incentive Plan, with all resolutions passing. Voting was conducted virtually, and results will be disclosed on SEDAR+ and via press release.
HLS Therapeutics Slides: Investor presentation
HLS Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
HLS Therapeutics resumed with a Hold at Canaccord
Canaccord resumed coverage of HLS Therapeutics (HLTRF) with a Hold rating and C$5 price target
HLS Therapeutics Q1 Earnings Call Highlights
HLS Therapeutics TSE: HLS reported modest first-quarter revenue growth and reaffirmed its 2026 outlook, while management highlighted early momentum for the company's newly launched cholesterol drug NI...
HLS Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw 2% revenue growth, strong Vascepa sales, and a successful NILEMDO launch with rapid private payer coverage. Operational improvements boosted cash flow and reduced net debt, while guidance for 2026 was reaffirmed and margin expansion is expected in the second half.
HLS Therapeutics Earnings release: Q1 2026
HLS Therapeutics released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
HLS Therapeutics Slides: Q1 2026
HLS Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 15, 2026.
HLS Therapeutics Slides: Corporate presentation
HLS Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
HLS Therapeutics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
Operational improvements and a strengthened balance sheet have set the stage for accelerated growth, with new cardiovascular launches like Nilemdo and NEXLIZET targeting significant unmet needs. Early market access wins and a robust product pipeline support a positive outlook through 2027.
HLS Therapeutics price target lowered to C$4.45 from C$4.75 at Stifel
Stifel lowered the firm’s price target on HLS Therapeutics (HLTRF) to C$4.45 from C$4.75 and keeps a Hold rating on the shares.
HLS Therapeutics Earnings Call Transcript: Q4 2025
Revenue for 2025 was $55.5M with 18% Adjusted EBITDA growth and strong cash flow. Vascepa demand rose 23%, NILEMDO launched in Canada, and net debt fell 23%. 2026 guidance is for modest revenue growth, with major expansion expected from NILEMDO and NEXLIZET launches.
HLS Therapeutics Earnings release: Q4 2025
HLS Therapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
HLS Therapeutics Slides: Q4 2025
HLS Therapeutics has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 12, 2026.
HLS Therapeutics price target raised to C$4.75 from C$4 at Stifel
Stifel raised the firm’s price target on HLS Therapeutics (HLTRF) to C$4.75 from C$4 and keeps a Hold rating on the shares.
HLS Therapeutics Earnings Call Transcript: Q3 2025
Adjusted EBITDA rose 19% in Q3 and 25% year-to-date, driven by operational improvements and cost discipline. Pasipa and Clozaril showed mixed performance, with strong growth in Western Canada and U.S. stability, while new cardiovascular launches are set to drive future growth.
HLS Therapeutics Slides: Q3 2025
HLS Therapeutics has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 13, 2025.
HLS Therapeutics Earnings release: Q3 2025
HLS Therapeutics released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
HLS Therapeutics Earnings Call Transcript: Q2 2025
Q2 2025 saw revenue of $14.2M and adjusted EBITDA up 21%, with strong cash flow growth and reduced debt. Vascepa and Clozaril showed solid performance, and preparations for Nexletol/Nexlizet launch are on track, with minimal incremental costs expected.
HLS Therapeutics Earnings release: Q2 2025
HLS Therapeutics released its Q2 2025 earnings on August 14, 2025, summarizing the period's financial results.
HLS Therapeutics Slides: Q2 2025
HLS Therapeutics has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 14, 2025.